Anti-leukotriene intervention: Is there adequate information for clinical use in asthma?

Respiratory Medicine

Volumn 90, Issue 10, 1996, Pages 575-586

  Ind, P W ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ADENOSINE; BECLOMETASONE DIPROPIONATE; BRADYKININ; CYTOKINE; HISTAMINE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PROSTAGLANDIN D2; PROSTAGLANDIN F2 ALPHA; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BIOSYNTHESIS; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; DYSPEPSIA; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MEDIATOR; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PHARYNGITIS; PRIORITY JOURNAL; REVIEW;

EID: 0029853512     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90015-3     Document Type: Review

References (70)

1. Djukanovic R, Roche WR, Wilson JW et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-457.
2. Diaz P, Gonzales MC, Galleguillos FR et al. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. Am Rev Respir Dis 1989; 139: 1383-1389.
3. Liu MC, Hubbard WC, Proud D et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator and permeability changes. Am Rev Respir Dis 1991; 144: 51-58.
4. Dahlen S-E, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 228: 484-486.
5. O'Hicky SP, Arm JP, Rees PJ, Spur BW, Lee TH. The relative responsiveness to inhaled leukotriene E4, methacholine and histamine in normal and asthmatic subjects. Eur Respir J 1988; I: 913-917.
6. Barnes NP, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4 and histamine in normal subjects. Thorax 1984; 39: 500-504.
7. Adelroth E, Morris MM, Hargreave FE, O'Byrne PM. Airway responsiveness to LTC4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315: 480-484.
8. Davidson AE, Lee TH, Scanlon PD, Solway J, McFadden R. Bronchoconstrictor effects of LTE4 in normal and asthmatic subjects. Am J Respir Dis 1987; 135: 333-337.
9. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. Slow-releasing substances, leukotrienes C4 and D4 increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1986; 126: 449-451.
10. Russie EW, Abraham WM. Effects of leukotriene D4 on mucociliary and respiratory function in allergic and nonallergic sheep. J Appl Physiol 1985; 59: 1416-1422.
11. Drazen JM, Austen KF, Lewis RA, Corey EJ. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 1980; 77: 4354-4358.
12. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995; 8: 1203-1213.
13. Sampson AP, Thomas RU, Costello JF, Piper PJ. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Pharmacol 1992; 33: 423-430.
14. Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes LTC4 and LTB4 in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989; 84: 19-26.
15. Lam S, Chan H, Leriche JC, Chan Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988; 81: 711-717.
16. Drazen JM, O'Brien J, Sparrow D et al. Recovery of leukotriene E4 from the urine of patients with airways obstruction. Am Rev Respir Dis 1992; 146: 104-108.
17. Smith CM, Hawksworth RJ, Thien FCK, Christie PE, Lee TH. Urinary leukotriene E4 in bronchial asthma. Eur Respir J 1992; 5: 693-699.
18. Smith CM, Christie PE, Hawskworth RJ, Thien F, Lee TH. Urinary leukotriene E4 levels following allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis 1991; 143: 1411-1413.
19. Makker HK, Lau LC, Thomson HW, Binks SM, Holgate ST. The protective effect of inhaled leukotriene D4 receptor antagonist ICI204219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147: 1413-1418.
20. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JJ. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 receptor antagonist. N Engl J Med 1990; 323; 1736-1739.
21. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988; 82: 654-660.
22. Smith LJ, Geller S, Ebright L, Glass M, Thyrum PT. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI204219. Am Rev Respir Dis 1990; 141: 988-992.
23. Smith LJ, Glass M, Minkwitz MC. Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: A concentration-effect study of ICI204219. Clin Pharmacol Ther 1993; 54: 430-436.
24. Jones JR, Kips JC, Pauwels RA, Van Der Straeten ME. The effects of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics. Pulm Pharmacol 1991; 4: 37-42.
25. Kips JC, Joos GF, Delepelaire I et al. MK-571: a potent antagonist of LTD4-induced bronchoconstriction in the human. Am Rev Respir Dis 1991; 144: 617-621.
26. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062-1063.
27. De Jong JE, van Vlijmen VI. Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK-886) in psoriasis. Skin Pharmacol 1991; 4: 278-285.
28. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI204219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994; 105: 483-488.
29. Taylor IK, O'Shaughnessy, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI204219 on allergen-induced bronchoconstriction and airways hyperreactivity in atopic subjects. Lancet 1991; 337: 690-694.
30. O'Shaughnessey KM, Taylor IK, O'Connor B, O'Connell F, Thomson H, Dollery CT. Potent leukotriene D4 receptor antagonist ICI204219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147: 1431-1435.
31. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist ICI204219 on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89: 1040-1045.
32. Dahlen B, Zetterstrom O, Bjorck T, Dahlen S-E. The leukotriene-antagonist ICI204219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994; 7: 324-331.
33. Bjorck T, Dahlen S-E. Leukotrienes and histamine mediated IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulm Pharmacol 1993; 6: 87-96.
34. Calhoun WJ, Lavins BJ, Glass M. Effect of Accolate* (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma. Am J Respir Crit Care Med 1995; 151: A42.
35. Britton JR, Hanley SP, Tattersfield AE. The effect of an oral leukotriene D4 antagonist L-649923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol 1987; 79: 811-816.
36. Rasmussen JB, Eriksson LO, Margolskee DJ, Tagari P, Williams VC, Andersson KE. Leukotriene D4 receptor blockade inhibits the immediate and late broncho-constrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992; 90: 193-201.
37. Kidney J, Ridge S, Chung KF, Barnes PJ. Inhibition of PAF-induced bronchoconstriction by the oral leukotriene D4 antagonist ICI204219. Am Rev Respir Dis 1993; 147: 215-217.
38. Hui KP, Taylor IK, Taylor GW et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184-189.
39. Rosenberg MA, Torres MJ, Valencia A et al. The effect of a 5-lipoxygenase (5-LO) inhibitor ABT-761 on inhaled house dust mite early asthmatic response. J Allergy Clin Immunol 1995; 95: (1 pt 2): 845.
40. Friedman BS, Bel EH, Buntinx A et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993; 147: 839-844.
41. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Am Rev Respir Dis 1992; 145: 746-749.
42. Robuschi M, Riva E, Fuccella LM et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene receptor antagonist SK&F104353. Am Rev Respir Dis 1992; 145: 1285-1288.
43. Glass M, Snader LA, Israel E. Effect of the inhaled LTD4-receptor antagonist ICI204219 on cold-air induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 1993; 93: 794.
44. Israel E, Dermarkarian R, Rosenberg M et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740-1744.
45. van Schoor J, Joos GF, Kips JC, Pauwels RA, Drajesk JF, Carpentier PJ. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatics. Am J Respir Crit Care Med 1995; 151: A376.
46. Israel E, Fischer AR, Rosenberg MA et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148 :1447-1451.
47. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist SK&F104353 inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957-958.
48. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen S-E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48: 1205-1210.
49. Nasser SMS, Bell GS, Foster S et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49: 749-756.
50. Kips JC, Joos GF, Felman AE, Pauwels RA. The effect of inhaled ICI204219 on baseline lung function in moderate asthma. Am Rev Respir Dis 1993; 147 (Suppl. 2): A297.
51. Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992; 146: 358-363.
52. Sorkness CA, Reiss TF, Zhang J et al. Bronchodilation with a selective and potent leukotriene D4 (LTD4) antagonist (MK-0476) in patients with asthma. Am J Respir Crit Care Med 1994; 149: A216.
53. Fuller RW, Black PN, Dollery CT. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and LTD4 in atopic subjects. J Allergy Clin Immunol 1989; 83: 939-944.
54. Bateman ED, Holgate ST, Binks SM, Tarns IP. A multicentred study to assess the steroid-sparing potential of Accolate* (zafirlukast 20 mg bd). Eur J Allergy Clin Immunol 1995; 50: 320 (P-0709).
55. Laitinen LA, Zetterstrom O, Holgate ST, Binks SM, Whitney JG. Effects of Accolate* (zafirlukast 20 mg bd) in permitting reduced therapy with inhaled steroids: a multicentre trial in patients with doses of inhaled steroid optimised between 800 and 2000 meg per day. Eur J Allergy Clin Immunol 1995; 50: 320 (P-0710).
56. Spector S, Miller CJ, Glass M. 13-week dose-response study with Accolate* (zafirlukast) in patients with mild to moderate asthma. Am J Respir Crit Care Med 1995; 151: A379.
57. Lockley RF, Lavins BJ, Snader L. Effects of 13 weeks of treatment with ICI204219 (Accolate*) in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 95: 839.
58. Kemp JP, Glass M, Minkwitz MC. Onset of action of the leukotriene-receptor antagonist, zafirlukast (Accolate*), in patients with asthma. J Allergy Clin Immunol 1995; 95: 841.
59. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI204219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618-623.
60. Israel E, Rubin P, Kemp JP et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119: 1059-1066.
61. Wempe JB, Postma DS, Breederveld N, Alting-Hebing D, van der Mark TW, Koeter GH. Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. J Allergy Clin Immunol 1992; 89: 679-687.
62. Liu M, Cohn J. Effects of zileuton, a 5-lipoxygenase inhibitor, in moderate asthma: results of a 6-month double-blind, placebo-controlled trial. Eur Respir J 1994; 7 (Suppl. 8): 1316.
63. Chapman KR, Friedman BS, Shingo S et al. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids. Am J Respir Crit Care Med 1994; 149: A215.
64. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol and salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062-1067.
65. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI204219 (Accolate*) or cromolyn sodium (Intal*) in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 95: 388: A990.
66. FDA Advisory Committee Meeting Transcript, 10 March 1995.
67. Schwartz HJ, Petty T, Reed R, Dube LM, Swanson LJ. The comparative effects of zileuton, a 5-lipoxygenase inhibitor, vs theophylline in patients with moderate asthma: results from a 13-week multicenter trial. Am J Respir Crit Care Med 1995; 151: A376.
68. Market Letter 8 April 1996, p. 21.
69. Alabaster VA, Moore BA. Drug intervention in asthma: present and future. Thorax 1993; 48: 176-182.
70. Godfrey S, Konig P. Treatment of childhood asthma for thirteen months and longer with beclomethasone diproprionate aerosol. Arch Dis Childhood 1974; 49: 591-596.